---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-030499"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T22:02:23.913900+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics shareholders approve all four proposals at 2023 annual meeting

## Summary
- Elected five directors: Cherington, Angel, Fiore, Wexler, Singer — each received >2.68M votes for, ~770K broker non-votes.
- Ratified Grant Thornton as auditor for FY 2023: 3.52M for, 23K against, 6K abstain.
- Approved potential issuance of >20% of outstanding shares under Lincoln Park Capital purchase agreement: 2.75M for, 27K against.
- Approved amendment to Restated 2020 Stock Incentive Plan, increasing reserved shares from 680,599 to 980,599: 2.62M for, 160K against.

## SEC filing metadata
- accession: 0001140361-23-030499
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/brhc20054589_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-030499
- JSON: https://secwatch.observer/filing/0001140361-23-030499.json
- Plain text: https://secwatch.observer/filing/0001140361-23-030499.txt

## Key facts
- Shareholder Votes
  Ernexa Therapeutics Inc. shareholders approved Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to potentially issuance and sell more than 20% of the Company's outstanding common stock pursuant to its purchase agreement with Lincoln Park Capital, LLC at the 2023-06-16 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 3 : Approval, for purposes of complying with Nasdaq Listing Rule 5635(d), to potentially issuance and sell more than 20% of the Company’s outstanding common stock pursuant to its purchase agreement with Lincoln Park Capital, LLC : Votes For Votes Against Abstentions Broker Non-Votes 2,751,635 26,798 2,027 769,743
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm
- Shareholder Votes
  Ernexa Therapeutics Inc. shareholders approved Approval of an amendment to the Company's Restated 2020 Stock Incentive Plan to increase the number of shares reserved for issuance from 680,599 shares to 980,599 shares at the 2023-06-16 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 4 : Approval of an amendment to the Company’s Restated 2020 Stock Incentive Plan to increase the number of shares reserved for issuance from 680,599 shares to 980,599 shares : Votes For Votes Against Abstentions Broker Non-Votes 2,615,319 160,415 4,726 769,743
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm
- Shareholder Votes
  Ernexa Therapeutics Inc. shareholders approved Election of five directors to the Board of Directors of the Company to hold office until the Company's 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified at the 2023-06-16 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 1 : Election of five directors to the Board of Directors of the Company to hold office until the Company’s 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Director Votes For Votes Withheld Broker Non-Votes Charles Cherington 2,731,140 49,320 769,743 Matthew Angel 2,761,115 19,345 769,743 Gregory Fiore 2,687,900 92,560 769,743 William Wexler 2,746,291 34,169 769,743 Nicholas J. Singer 2,757,575 22,885 769,743
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm
- Shareholder Votes
  Ernexa Therapeutics Inc. shareholders approved Ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the 2023 fiscal year at the 2023-06-16 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-16
  source text: Proposal 2 : Ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year: Votes For Votes Against Abstentions Broker Non-Votes 3,520,765 23,287 6,151 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.